Urinary Angiotensinogen Could Be a Prognostic Marker of Renoprotective Effects of Alogliptin in Patients with Type 2 Diabetes

Table 1

Patient profiles.

	43
Men/women	25/18
Age (years)	66.1 ± 1.71
BMI (kg/m^2)	24.8 ± 0.5
Treatment duration of T2D (years)	7.1 ± 1.18
Medications
ARB	23 (53.5%)
-GI	8 (18.6%)
TZD	5 (11.6%)

ARB: angiotensin II receptor blockers, -GI: -glucosidase inhibitors, and TZD: thiazolidines.